News
WisdomTree US High Dividend ETF (DHS) focuses on high-yield, quality U.S. equities, favoring defensive sectors. Read an ...
New research from Bayes Business School, in collaboration with biopharmaceuticals company Merck KGaA, suggests member states from the European Union (EU) must work more closely together, provide ...
The American Association for Cancer Research’s annual conference featured updates from several companies on key candidates ...
Merck has initiated construction of a $1 billion, 470,000-square-foot biologics center of excellence in Wilmington, Delaware.
Located at Chestnut Run Innovation & Science Park, the Merck Wilmington Biotech project will comprise laboratory, ...
Summit, a specialist in oncology, has made excellent clinical progress with its leading candidate, ivonescimab. There's more where that came from, too; Ivonescimab just knocked it out of the park in ...
Gastric cancer remains a major health challenge worldwide, with nearly 1 million new cases annually contributing to more than ...
1d
MedPage Today on MSNOncologists Dish on Insurers; 'Torrent of Hate' After Diagnosis; More Risky TanningMore than 80% of oncologists participating in a global survey consider insurance a major barrier to timely cancer care.
AmacaThera, a clinical-stage biotechnology company specializing in drug delivery, announced it has signed a binding ...
The new policy, revealed by the Department of Health and Human Services on Wednesday, would make vaccines “less available and ...
Can ctDNA-guided therapy stop cancer’s return, sparing patients unnecessary treatment? A new study suggests it might.
Arvinas is laying off about a third of its workforce, while Entrada is focusing more on Duchenne research. Elsewhere, Biogen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results